Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tscan Therapeutics Inc (TCRX)

Tscan Therapeutics Inc (TCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 158,512
  • Shares Outstanding, K 53,371
  • Annual Sales, $ 21,050 K
  • Annual Income, $ -89,220 K
  • EBIT $ -119 M
  • EBITDA $ -114 M
  • 60-Month Beta 0.79
  • Price/Sales 7.43
  • Price/Cash Flow N/A
  • Price/Book 0.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.27
  • Number of Estimates 4
  • High Estimate -0.24
  • Low Estimate -0.30
  • Prior Year -0.21
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.60 +14.23%
on 12/11/24
4.94 -39.88%
on 11/29/24
-1.15 (-27.91%)
since 11/20/24
3-Month
2.60 +14.23%
on 12/11/24
6.22 -52.29%
on 11/07/24
-2.55 (-46.20%)
since 09/20/24
52-Week
2.60 +14.23%
on 12/11/24
9.69 -69.35%
on 05/21/24
-1.87 (-38.64%)
since 12/20/23

Most Recent Stories

More News
2 "Strong Buy"-Rated Biotech Stocks With 303% to 446% Upside Potential

While the upside is appealing, penny stocks carry some risks.

TCRX : 2.97 (+1.37%)
$SPX : 5,930.85 (+1.09%)
SCPH : 3.39 (+2.42%)
Insider Purchase: 10% owner at $TCRX (TCRX) Buys 31,800 Shares

Capital Management LP Lynx1, a 10% owner of $TCRX ($TCRX), bought 31,800 shares of the company on 12-12-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

TCRX : 2.97 (+1.37%)
TScan Therapeutics Reports Positive Preliminary Results from ALLOHA Phase 1 Trial and Announces Upcoming Virtual KOL Event

TScan Therapeutics reports positive Phase 1 trial results for TCR-T therapies in leukemia, with a KOL event scheduled.Quiver AI SummaryTScan Therapeutics, Inc. reported promising results from the ongoing...

TCRX : 2.97 (+1.37%)
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

TCRX : 2.97 (+1.37%)
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

TCRX : 2.97 (+1.37%)
TScan Therapeutics to Host Virtual KOL Event Discussing ALLOHA Phase 1 Trial Data and Clinical Development Strategy

TScan Therapeutics will host a virtual KOL event on December 10 to discuss Phase 1 trial data and development strategies.Quiver AI SummaryTScan Therapeutics, Inc., a biotechnology company focused on T...

TCRX : 2.97 (+1.37%)
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

TCRX : 2.97 (+1.37%)
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

TCRX : 2.97 (+1.37%)
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

TCRX : 2.97 (+1.37%)
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

TCRX : 2.97 (+1.37%)

Business Summary

TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 3.24
2nd Resistance Point 3.14
1st Resistance Point 3.06
Last Price 2.97
1st Support Level 2.88
2nd Support Level 2.78
3rd Support Level 2.70

See More

52-Week High 9.69
Fibonacci 61.8% 6.98
Fibonacci 50% 6.14
Fibonacci 38.2% 5.31
Last Price 2.97
52-Week Low 2.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar